Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.